Partial
Needs Revision
Patient Risk:
Moderate
Summary
Partially aligned: acne indication and core administration/pregnancy/sun protection concepts are supported, but multiple clinically and safety-relevant claims (e.g., psoriasis indication and frequency of specific irritation effects; vitamin A derivative phrasing; specific strength percentages) are unsupported by the provided labeling excerpts.
Category Scores
Accurate Statements
Tazarotene is a topical medicine in the retinoid family.
11 DESCRIPTION (member of the acetylenic class of retinoids; topical administration)
Tazarotene is used to treat certain skin conditions such as acne.
1 INDICATIONS AND USAGE (topical treatment of acne vulgaris in patients 9 years of age and older)
Topical tazarotene commonly is applied in a thin layer.
2 DOSAGE AND ADMINISTRATION (Apply a thin layer of ARAZLO to the affected areas once daily.)
Topical tazarotene is typically started less frequently if irritation occurs, then increased as tolerated.
17 PATIENT COUNSELING INFORMATION (reduce frequency, temporarily interrupt treatment, or discontinue; treatment may be resumed once irritation subsides)
Tazarotene requires use of sun protection because retinoids can increase sun sensitivity.
5.3 Photosensitivity and Risk for Sunburn (minimize unprotected UV exposure; use sunscreen/protective clothing); 2 DOSAGE AND ADMINISTRATION (Use effective sunscreens and wear protective clothing)
Tazarotene should be avoided during pregnancy.
8.1 Pregnancy (ARAZLO is contraindicated in pregnancy; may cause fetal harm and should be discontinued as soon as pregnancy is recognized)
Tazarotene should be avoided on irritated or broken skin.
17 PATIENT COUNSELING INFORMATION (avoid applying ARAZLO to eczematous or sunburned skin; manage undue irritation)
Unsupported Statements
Tazarotene is a vitamin A derivative.
Not supported by the provided label excerpts (11 DESCRIPTION does not state 'vitamin A derivative').
Tazarotene is used to treat certain skin conditions such as psoriasis.
Psoriasis indication is not supported by the provided label excerpt for ARAZLO (1 INDICATIONS AND USAGE only cites acne vulgaris).
Tazarotene products are typically sold as topical formulations at different strengths.
The provided label shows only one strength/formulation for ARAZLO (0.045% lotion); 'typically sold' and 'different strengths' are not substantiated.
Tazarotene commonly includes 0.05% and 0.1% strengths.
Not supported by the provided label excerpt (3 DOSAGE FORMS AND STRENGTHS lists only 0.045% ARAZLO).
0.05% and 0.1% tazarotene are often used for acne.
Not supported by the provided label excerpt (no 0.05%/0.1% strengths and no linkage of those strengths to acne).
Higher-strength tazarotene may be used for specific psoriasis indications depending on local approval and labeling.
Not supported by the provided label excerpts.
Topical tazarotene commonly causes irritation, especially at the start of treatment.
The provided excerpts include guidance about 'Skin Irritation' counseling but do not support 'commonly' or 'especially at the start' as labeled frequency/timing.
Topical tazarotene commonly causes redness.
The provided excerpts do not support 'commonly causes redness' as an adverse reaction claim.
Topical tazarotene commonly causes peeling.
The provided excerpts do not support 'commonly causes peeling' as an adverse reaction claim.
Topical tazarotene commonly causes dryness.
The provided excerpts do not support 'commonly causes dryness' as an adverse reaction claim.
Topical tazarotene commonly causes burning or stinging.
The provided excerpts do not support 'commonly causes burning or stinging' as an adverse reaction claim.
Topical tazarotene is typically applied to clean, dry skin.
Not supported by the provided label excerpts.
Retinoids are associated with birth-defect risk with systemic exposure.
Not supported by the provided label excerpts as stated (8.1 Pregnancy does discuss fetal harm and contraindication, but the specific wording about 'systemic exposure' risk for 'retinoids' is not provided in the excerpt evidence given).
Topical tazarotene products carry pregnancy warnings on labeling in many countries.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
The label-specific dosing regimen for ARAZLO includes once-daily application and key avoidance areas (eyes, mouth, paranasal creases, mucous membranes) and rinsing instructions if it gets in/near eyes.
Importance:
Moderate
Age restriction for the labeled indication (acne vulgaris in patients 9 years of age and older) was not stated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about psoriasis indications and frequency of irritation-related adverse effects (redness/peeling/dryness/burning) could mislead expectations and appropriate use. Pregnancy contraindication and sun-protection guidance were supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Several major claims are not supported by the provided ARAZLO label excerpts, including psoriasis indication, specific concentration strengths (0.05%/0.1%), and 'commonly causes' adverse reactions/frequency language.
Suggested Improvement
Restrict claims to the provided label: acne vulgaris indication for ARAZLO 0.045% in patients ≥9 years; use label-supported language for skin irritation and photosensitivity; omit unsupported concentration/generalization and psoriasis statements unless supported by the specific product label.